Analyst Ratings For Oncobiologics (NASDAQ:ONS)
Today, Oncobiologics (NASDAQ:ONS) stock was downgraded by Barclays from Overweight to Equal Weight.
Some recent analyst ratings include
- 1/29/2018-Barclays was Downgraded by analysts at Barclays from a “Overweight ” rating to a ” Equal Weight” rating.
- 4/13/2017-Cantor Fitzgerald Reiterated Rating of Buy.
- 4/12/2017-Jefferies Group Reiterated Rating of Hold.
Recent Insider Trading Activity For Oncobiologics (NASDAQ:ONS)
Oncobiologics (NASDAQ:ONS) has insider ownership of 33.50% and institutional ownership of 17.90%.
- On 1/4/2018 Pankaj Mohan, CEO, sold 114,677 with an average share price of $1.17 per share and the total transaction amounting to $134,172.09.
- On 12/22/2017 Elizabeth A. Yamashita, VP, sold 16,170 with an average share price of $1.13 per share and the total transaction amounting to $18,272.10.
- On 12/22/2017 Lawrence A. Kenyon, CFO, sold 26,165 with an average share price of $1.13 per share and the total transaction amounting to $29,566.45.
- On 12/22/2017 Stephen J Mcandrew, SVP, sold 15,705 with an average share price of $1.13 per share and the total transaction amounting to $17,746.65.
- On 12/19/2017 Elizabeth A. Yamashita, VP, sold 7,660 with an average share price of $1.15 per share and the total transaction amounting to $8,809.00.
- On 12/19/2017 Pankaj Mohan, CEO, sold 104,131 with an average share price of $1.15 per share and the total transaction amounting to $119,750.65.
- On 11/11/2016 Scott A. Gangloff, SVP, sold 37,369 with an average share price of $3.75 per share and the total transaction amounting to $140,133.75.
Recent Trading Activity for Oncobiologics (NASDAQ:ONS)
Shares of Oncobiologics closed the previous trading session at 1.17 down -0.03 2.49% with 1.1799999475479126 shares trading hands.
